Publications by authors named "E Capparelli"
Background: Vertical HIV-1 transmission despite antiretroviral therapy may be mitigated by use of long-acting, broadly neutralizing, monoclonal antibodies (bNAb) such as VRC07523LS. The present study was designed to determine the safety and pharmacokinetics of VRC07523LS.
Methods: VRC07523LS, 80 mg/dose, was administered subcutaneously after birth to non-breastfed (Cohort 1; N=11, enrolled in USA) and breastfed (Cohort 2; N=11, enrolled in South Africa and Zimbabwe) infants exposed to HIV-1.
Introduction: Human papillomavirus (HPV) infection is a widespread skin-to-skin transmitted infection that poses a global health concern. Although Albania faced prior challenges, it has recently introduced a quadrivalent recombinant HPV vaccine, a critical step in preventing cervical cancer among young women. This study aims to identify potential gaps in knowledge and attitudes among Albanian women regarding cervical cancer and HPV infection, as well as provide insights into the effectiveness of the national primary prevention program.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on understanding neuropathic pain in different types of spondyloarthritis (SpA), such as axial SpA, psoriatic arthritis, and undifferentiated peripheral SpA, aiming to identify its prevalence, characteristics, and risk factors.
- Conducted at two rheumatology centers, the research involved 177 patients and utilized specific questionnaires to assess neuropathic pain, revealing that 22.2% likely experienced significant neuropathic pain while 64.9% showed no significant issues.
- Findings indicated that factors like gender and obesity influenced pain scores, and notable correlations were found between neuropathic pain and clinical disease activity, stressing the need for routine pain assessments in SpA treatment.
Objectives: To develop a pragmatic twice daily lamivudine dosing strategy for preterm infants from 24 to 37 completed weeks of gestation.
Methods: Data were combined from eight pharmacokinetic studies in neonates and infants receiving lamivudine oral solution. A population pharmacokinetic model was developed using non-linear mixed effects regression.
Objectives: To confirm that levetiracetam (LEV) demonstrates predictable pharmacokinetics(PK) at higher doses and to study the pharmacodynamics(PD) of LEV.
Design: Pharmacokinetic data from the NEOLEV1 and NEOLEV2 trials were analysed using a non-linear mixed effects modelling approach. A post hoc analysis of the effect of LEV on seizure burden was conducted.